Previous study found that prostate cancer patients who responded to docetaxel and zolendronic acid therapy had a 35% decrease in overall serum IL-6 levels, while patients who did not respond had an increasing in serum IL-6 levels, which implied IL-6 regulate chemo-resistance in prostate cancer [8, 11]. Here, IL6 is linked to Familial prostate cancer.